OMB APPROVAL
OMB Number: 3235-0416 Expires: April 30, 2009 Estimated average burden hours per response 182.00

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

[**X**] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934
For the quarterly period ended August 31, 2007

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934
For the transition period from ________ to ________

Commission file number: 000-49685

Bi-Optic Ventures Inc.

(Name of small business issuer in its charter)

British Columbia, Canada
(Jurisdiction of Incorporation/Organization)

N/A
(IRS Tax ID No.)

1030 West Georgia Street #1518, Vancouver, British Columbia, Canada V6E 2Y3
(Address of principal executive offices)

Issuer's Telephone Number: 604-689-2646

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes xxx No ____

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes xxx No ____

Indicate the number of shares outstanding of each of the issuer's classes of common stock as of 9/30/2007: 10,012,235 Common Shares w/o par value

Transitional Small Business Disclosure Format (Check one):Yes ___ No xxx

SEC 2334 (11-06) Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

PART I
FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BI-OPTIC VENTURES INC.

FINANCIAL STATEMENTS

SIX MONTHS ENDED

AUGUST 31, 2007 AND 2006

Bi-Optic Ventures Inc.
(A Development Stage Company)
Balance Sheets
(expressed in Canadian dollars)

	August 31, 2007 $ (unaudited)	February 28, 2007 $
Assets		
Current Assets		
Cash	14,494	–
Amounts receivable	3,693	6,642
Prepaid expenses and deposits	33,592	5,921
Loan receivable (Note 5)	10,726	–
Total Current Assets	62,505	12,563
Property and Equipment (Note 3)	16,079	14,138
Deferred Acquisition Costs (Note 5)	5,456	–
Total Assets	84,040	26,701
Liabilities and Stockholders' Deficit		
Current Liabilities		
Cheques issued in excess of funds on deposit	–	830
Accounts payable	34,069	49,376
Accrued liabilities	1,325	1,600
Loans payable (Note 6)	70,409	–
Due to related parties (Note 4)	155,018	21,186
Total Liabilities	260,821	72,992
Contingencies (Note1)		
Commitments (Note 5 and 6)		
Subsequent Event (Note 7)		
Stockholders' Deficit		
Common Stock: Unlimited common shares authorized without par value; 10,012,235 shares issued and outstanding	3,768,180	3,768,180
Deficit Accumulated During the Development Stage	(3,944,961)	(3,814,471)
Total Stockholders' Deficit	(176,781)	(46,291)
Total Liabilities and Stockholders' Deficit	84,040	26,701

(The accompanying notes are an integral part of the financial statements)

Bi-Optic Ventures Inc.
(A Development Stage Company)
Statements of Operations
(expressed in Canadian dollars)
(unaudited)

	Accumulated from May 31, 1984 (Date of Inception) to August 31, 2007	Three months ended August 31,		Six months ended August 31,	
	2007	2007	2006	2007	2006
	$	$	$	$	$
Revenue	–	–	–	–	–
Expenses					
Acquisition costs written off	347,815	–	–	–	–
Amortization	12,195	1,590	287	2,512	573
Bad debts	20,658	–	–	–	–
Consulting and management fees (Note 4(a))	577,161	24,777	13,265	39,107	56,266
Investor and public relations	86,868	1,929	1,400	3,229	2,700
Office, rent and telephone (Note 4(b))	343,857	18,584	12,673	31,820	24,023
Professional fees (Note 4(c))	489,779	4,144	12,291	28,464	39,195
Transfer agent and regulatory fees	98,602	5,693	7,983	7,623	10,105
Travel and promotion	296,817	7,870	23,950	17,735	44,275
Total Expenses	2,273,752	64,587	71,849	130,490	177,137
Loss from Operations	(2,273,752)	(64,587)	(71,849)	(130,490)	(177,137)
Other Income					
Accounts payable written off	49,341	–	–	–	–
Interest and other income	13,729	–	–	–	–
Total Other Income	63,070	–	–	–	–
Net Loss Before Discontinued Operations	(2,210,682)	(64,587)	(71,849)	(130,490)	(177,137)
Loss from Discontinued Operations	(1,734,279)	–	–	–	–
Net Loss for the Period	(3,944,961)	(64,587)	(71,849)	(130,490)	(177,137)
Net Loss Per Share – Basic and Diluted		(0.01)	(0.01)	(0.01)	(0.02)
Weighted Average Shares Outstanding		10,012,235	9,190,000	10,012,235	9,149,000

(The accompanying notes are an integral part of the financial statements)

Bi-Optic Ventures Inc.
(A Development Stage Company)
Statements of Cash Flows
(expressed in Canadian dollars)
(unaudited)

	Three Months Ended August 31, 2007 $	Three Months Ended August 31, 2006 $	Six Months Ended August 31, 2007 $	Six Months Ended August 31, 2006 $
Operating Activities				
Net loss	(64,587)	(71,849)	(130,490)	(177,137)
Adjustment to reconcile net loss to net cash used in operating activities				
Amortization	1,590	287	2,512	573
Changes in operating assets and liabilities				
Amounts receivable	(10,817)	(1,197)	(7,777)	(1,225)
Prepaid expenses and deposits	(2,909)	(1,198)	(27,671)	5,802
Cheques issued in excess of funds on deposit	–	438	(830)	438
Accounts payable and accrued liabilities	(29,292)	5,844	(15,582)	16,903
Due to related parties	53,375	18,658	133,832	24,990
Net Cash Used in Operating Activities	(52,640)	(49,017)	(46,006)	(129,656)
Investing Activities				
Deferred acquisition costs	–	–	(5,456)	–
Acquisition of property and equipment	(4,453)	–	(4,453)	–
Net Cash Used in Investing Activities	(4,453)	–	(9,909)	–
Financing Activities				
Proceeds from loans payable	70,409	–	70,409	–
Issuance of common shares, net of costs	–	47,700	–	53,700
Net Cash Provided By Financing Activities	70,409	47,700	70,409	53,700
Change in Cash	13,316	(1,317)	14,494	(75,956)
Cash - Beginning of Period	1,178	1,317	–	75,956
Cash - End of Period	14,494	–	14,494	–
Supplemental Disclosures				
Interest paid	–	–	–	–
Income taxes paid	–	–	–	–

(The accompanying notes are an integral part of the financial statements)

1. Nature of Operations and Continuance of Business

Bi-Optic Ventures Inc. (the “Company”) was incorporated in the Province of British Columbia, Canada on May 31, 1984. The Company filed a 10-SB Registration Statement with the U.S. Securities Exchange Commission in 2003. On March 22, 2007, the Company entered into an agreement to acquire Pacific Bio-Pharmaceuticals, Inc. (“Pacific”). See Note 5.

The Company is in the earliest development stage. In a development stage company, management devotes most of its activities in evaluating various business opportunities. The ability of the Company to emerge from the development stage is dependent upon its successful efforts in evaluating and acquiring or developing a business opportunity, raising additional equity financing and/or generating significant revenue. There is no guarantee that the Company will be able to raise enough equity to develop and implement a business plan. As at August 31, 2007, the Company has a working capital deficit of $198,316, has incurred operating losses since inception totalling $3,944,961 and has not generated any revenues since its inception. Based on the above factors, there is substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Summary of Significant Accounting Policies

(a) Basis of Presentation

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in Canadian dollars. The Company has not produced any revenue and is a development stage company as defined by Statement of Financial Accounting Standard (“SFAS”) No. 7. There are no financial statements using Canadian generally accepted accounting principles, however, there would be no material reconciling items other than presentation items.

(b) Use of Estimates

The preparation of financial statements in accordance with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to the recoverability of long-lived assets and deferred income tax asset valuations. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

(c) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

2. Summary of Significant Accounting Policies (continued)

(d) Property and Equipment

Property and equipment is recorded at cost. Amortization is computed on a declining balance basis at the following rates:

Computer equipment	30%
Furniture and equipment	20%
Leasehold improvements	5 years straight line

(e) Long-lived Assets

In accordance with SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets”, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

(f) Income Taxes

The Company accounts for income taxes using the asset and liability method in accordance with SFAS No. 109, “Accounting for Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.

(g) Financial Instruments

The carrying values of cash, amounts receivable, accounts payable, accrued liabilities and due to related parties approximate their fair values due to the relatively short maturity of these instruments.

(h) Foreign Currency Translation

The Company’s functional and reporting currency is the Canadian dollar. Occasional transactions may occur in U.S. dollars and management has adopted SFAS No. 52 “Foreign Currency Translation”. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Average monthly rates are used to translate revenues and expenses. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. The Company has not, to the date of these financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.

2. Summary of Significant Accounting Policies (continued)

(i) Comprehensive Loss

SFAS No. 130, “Reporting Comprehensive Income,” establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at August 31, 2007 and 2006, the Company has no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.

(j) Basic and Diluted Net Income (Loss) per Share

The Company computes net income (loss) per share in accordance with SFAS No. 128, "Earnings per Share" SFAS No. 128 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible preferred stock, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential common shares if their effect is anti-dilutive.

(k) Stock-based Compensation

Prior to March 1, 2006, the Company accounted for stock based awards under SFAS No. 123, “*Accounting for Stock-Based Compensation*”. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued. Effective March 1, 2006, the Company adopted the fair value recognition provisions of SFAS No. 123R “*Share Based Payments*”, using the modified retrospective transition method. The Company does not currently have a stock option plan. Accordingly, there was no effect on the Company’s reported loss from operations, cash flows or loss per share as a result of adopting SFAS No 123R.

Common shares issued to third parties for non-cash consideration are valued based on the fair market value of the services provided or the fair market value of the common stock on the measurement date, whichever is more readily determinable.

(l) Recent Accounting Pronouncements

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities – Including an Amendment of FASB Statement No. 115”. This statement permits entities to choose to measure many financial instruments and certain other items at fair value. Most of the provisions of SFAS No. 159 apply only to entities that elect the fair value option. However, the amendment to SFAS No. 115 “Accounting for Certain Investments in Debt and Equity Securities” applies to all entities with available-for-sale and trading securities. SFAS No. 159 is effective as of the beginning of an entity’s first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provision of SFAS No. 157, “Fair Value Measurements”. The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.

(expressed in Canadian dollars)

2. Summary of Significant Accounting Policies (continued)

(l) Recent Accounting Pronouncements (continued)

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements”. The objective of SFAS No. 157 is to increase consistency and comparability in fair value measurements and to expand disclosures about fair value measurements. SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS No. 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. The provisions of SFAS No. 157 are effective for fair value measurements made in fiscal years beginning after November 15, 2007. The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.

(m) Interim Financial Statements

These interim unaudited financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

3. Property and Equipment

	Cost $	Accumulated Amortization $	August 31, 2007 Net Carrying Value $	February 28, 2007 Net Carrying Value $
Computer equipment	16,787	6,734	10,053	7,374
Furniture and equipment	6,932	5,832	1,100	1,223
Leasehold improvements	6,157	1,231	4,926	5,541
	29,876	13,797	16,079	14,138

4. Related Party Transactions

(a) For the six months ended August 31, 2007, the Company paid or accrued $15,000 (2006 - $15,000) in management fees to a company controlled by the President of the Company.

(b) For the six months ended August 31, 2007, the Company paid $15,000 (2006 - $15,000) in rent to a company controlled by the President of the Company.

(c) For the three months ended August 31, 2007, the Company paid $9,000 (2006 - $9,000) in professional fees to a company controlled by a director.

(d) As at August 31, 2007, an amount of $45,768 (February 28, 2007 - $8,186) is owed to the President of the Company and is without interest, unsecured and due on demand.

(e) As at August 31, 2007, an amount of $109,250 (February 28, 2007 - $13,000) is owed to companies controlled by the President of the Company and is without interest, unsecured and due on demand.

5. Commitments

On March 22, 2007 the Company entered into an agreement with Pacific, PRB Pharmaceuticals, Inc. ("PRB"), and all of the shareholders of Pacific pursuant to which the Company has agreed to acquire all of the issued and outstanding shares and share purchase warrants of Pacific in exchange for one common share and one share purchase warrant of the Company, as applicable (the "Acquisition"). The Company has agreed to issue a maximum of 20,000,000 common shares and 2,500,000 share purchase warrants to acquire Pacific, assuming the completion of Pacific's planned private placement financing prior to the closing of the Acquisition. Pacific is a privately held Nevada corporation with offices in California that holds rights, directly and through a license from PRB, to certain biopharmaceutical technologies that have demonstrated potential effectiveness against several influenza strains. Provisional patent applications have been made in the United States for certain aspects of the technologies.

Concurrently with the closing, the Company will change its name to "Pacific Bio-Pharmaceuticals International Inc.", or such other name as may be determined by the directors, subject to TSX Venture Exchange (the “Exchange”) and shareholder approval.

A finder’s fee of 500,000 common shares will be payable by the Company on closing of the Acquisition subject to Exchange approval.

On June 1, 2007, the Company announced it had terminated its previous sponsorship agreement with Gateway Securities Inc. The Company has entered into a new sponsorship agreement with Global Maxfin Capital Inc. (“Global”). Global has, subject to completion of satisfactory due diligence, agreed to act as sponsor to the Company in connection with the acquisition of Pacific. Under the terms of the sponsorship agreement, Global will be paid $15,000 plus reimbursement for its reasonable out-of-pocket expenses and disbursements including legal fees incurred.

The Company also changed the terms of the private placement as disclosed above. The new private placement will be a non-brokered placement of up to 4,000,000 units at a price of $0.50 per unit for gross proceeds of up to $2,000,000. Each unit will consist of one common share and one-half transferable share purchase warrant. Each whole purchase warrant will be exercisable into one common share for a period of one year from closing at a price of $0.65 per share. An additional finder’s fee of cash and share purchase warrants, in accordance with Exchange policies, will be paid on a portion of the placement.

On August 31, 2007, the Company advanced $10,726 (US$10,000) to Pacific which is non-interest bearing, unsecured and due on demand.

6. Loans Payable

During the three months ended August 31, 2007, the Company received loan proceeds of $60,000 and $10,409 (US$10,000) from a non-related third party. The loans bear interest at 1.5% per month, are secured by promissory notes and are due on demand. If the acquisition of Pacific is completed, the Company is obligated to issue a total of 28,000 common shares to the lender.

7. Subsequent Event

On September 1, 2007, the Company received loan proceeds of $75,000 from the spouse of the President of the Company. The loan bears interest at 1.5% per month, is secured by a promissory note and is due on demand. If the acquisition is completed, the Company is obligated to issue 30,000 common shares to the lender.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-QSB contains forward-looking statements, principally in ITEM #2, "Management's Discussion and Analysis of Financial Condition and Results of Operations". These statements may be identified by the use of words like "plan", "expect", "aim", "believe", "project", "anticipate", "intend", "estimate", "will", "should", "could" and similar expressions in connection with any discussion, expectation, or projection of future operating or financial performance, events or trends. In particular, these include statements about the Company's strategy for growth, property exploration, mineral prices, future performance or results of current or anticipated mineral production, interest rates, foreign exchange rates, and the outcome of contingencies, such as acquisitions and/or legal proceedings.

Forward-looking statements are based on certain assumptions and expectations of future events that are subject to risks and uncertainties. Actual future results and trends may differ materially from historical results or those projected in any such forward-looking statements depending on a variety of factors, including, among other things, the factors discussed in this Registration Statement under ITEM #3, "Key Information, Risk Factors" and factors described in documents that we may furnish from time to time to the Securities and Exchange Commission. We undertake no obligation to update publicly or revise any forward-looking statements because of new information, future events or otherwise.

Results of Operations

The Company has not had any sources of revenue to date and has financed its activities substantially through equity financing. The Company has incurred net losses each year since inception and, as of 8/31/2007 had an accumulated deficit of ($3,944,961).

On 3/22/2007, the Company agreed to acquire Pacific Bio-Pharmaceuticals, Inc. The Company also announced two planned private placements intended to raise up to $2 million through the issuance of 4,000,000 units. Also, the Company announced plans, pending completion of the acquisition, to name new officers/directors and to change the corporate name. Completion of the Acquisition is subject to a number of conditions, including but not limited to, TSX Venture Exchange acceptance, disinterested shareholder approval, and successful due diligence by all parties. The transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. **At this time, completion cannot be considered "probable".**

Operating Expenses for the Six Months Ended 8/31/2007 were $130,490 [compared to $177,137 for the same period last year] which included consulting/management fees of $39,107 (2006 = $56,266), office/rent/telephone of $31,820 (2006 = $24,023), professional fees of $28,464 (2006 = $39,195), and travel/promotion expenses of $17,735 (2006 = $44,275). The reported decrease was related to the current pending status of a potential acquisition versus last year's extensive search for, the negotiations with, and due diligence on potential acquisitions. Net Loss for the Six Months was ($130,490) vs. ($177,137). Loss Per Share was ($0.01) vs ($0.02).

Liquidity and Capital Resources

The Company had a working capital deficit of ($198,316) at 8/31/2007, compared to a working capital deficit of ($60,429) at 2/28/2007. However, on 9/1/2007, the Company received loan proceeds of $75,000 from a related party. Cash Used by Operating Activities was ($46,006), including the ($130,490) Net Loss; $81,972 net changes in operating assets/liabilities was the significant adjustment; much of this was the $133,832 in "due to related parties" regarding advances and loans made to the Company, and the ($27,671) increase in "pre-paid expenses" regarding advances to various parties in connection with due diligence and sponsorship expenses with respect to the Company's proposed acquisition of Pacific Bio-Pharmaceuticals, Inc. Net Cash Provided by Financing Activities and Net Cash Used in Investing Activities was $70,409 in proceeds from loans payable. Net Cash Used by Investing Activities was $9,909.

ITEM 3. CONTROLS AND PROCEDURES

At the end of second fiscal quarter ended 8/31/2007 (the "Evaluation Date"), under the supervision and with the participation of the Company's management, including its Chief Executive Officer and Chief Financial Officer, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures (as defined in Rule 13a-15e under the Exchange Act). Based upon that evaluation, the Company's management, including the Chief Executive Officer and Chief Financial Officer, concluded that, as of the Evaluation Date, concluded that the Company's disclosure controls and procedures were effective to ensure that information the Company is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

The Company's management, including the Chief Executive Officer and Chief Financial Officer, identified no change in the Company's internal control over financial reporting that occurred during the Company's Fiscal Quarter Ended August 31, 2007 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II
OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

No Disclosure Necessary.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

a. No Disclosure Necessary.
b. No Disclosure Necessary.
c. No Disclosure Necessary.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

No Disclosure Necessary.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No Disclosure Necessary.

ITEM 5. OTHER INFORMATION

a. Reports on Form 8-K:
   1. Form 8-K filed 8/24/2007 regarding 6/1/2007 Press Release discussing FD Disclosure regarding “Termination of Sponsorship Agreement” and “Amended Private Placement”

   2. Form 8-K filed 7/27/2007 regarding FD Disclosure regarding “Postponement of Extra-Ordinary General Meeting of Shareholders”

   3. Form 8-K filed 7/16/2007 regarding 7/3/2007 Press Release discussing FD Disclosure regarding “Negotiation of Bridge Loan”

   4. Form 8-K filed 7/16/2007 regarding 6/20/2007 “Notice and Record Date” discussing FD Disclosure regarding upcoming AGM.

b. Information required by Item 401(g) of Regulation S-B:
   No Disclosure Necessary.

ITEM 6. EXHIBITS

Exhibit 31.1
Certification required by Rule 13a-14(a) or Rule 15d-14(a)

Exhibit 32.1
Certification Required by Rule 13a-14(b) or Rule 15d-14(b) and section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Bi-Optic Ventures Inc. -– SEC File No. 000-49685
Registrant

Date: October 11, 2007 /s/ Harry Chew
Harry Chew, President/Director

Exhibit 31.1
CERTIFICATIONS

I, Harry Chew, certify that:

(1) I have reviewed this Form 10-QSB of Bi-Optic Ventures, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

(4) I am responsible for establishing and maintaining disclosure controls and procedures [as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)] and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and

(5) I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: October 11, 2007

/s/ Harry Chew
Harry Chew, Chief Executive Officer and Chief Financial Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO THE SARBANES-OXLEY ACT
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

I, Harry Chew, Chief Executive Officer and Chief Financial Officer of Bi-Optic Ventures, Inc. (the "Company") do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. This Quarterly Report on Form 10-QSB of the Company for the period ended August 31, 2007 as filed with the Securities and Exchange Commission (the "report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 11, 2007

/s/ Harry Chew
Harry Chew, Chief Executive Officer and Chief Financial Officer